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Abstract: Thrombotic strokes can affect large or small arteries in the brain. Drugs to prevent atherosclerosis complication 
such as thrombotic strokes, should be drugs able to prevent the accumulation of intravascular fat, reduce vascular prolif-
eration, decease blood pressure levels with the resulting shear stress, reduce platelet aggregation, and possibly partially or 
totally reverse carotid plaques. Any of the commonly used antihypertensive drugs lower the incidence of stroke, with 
larger reductions in BP resulting in larger reductions in risk. Experimental and clinical data suggest that reducing the ac-
tivity of the renin-angiotensin aldosterone system (RAAS) may have beneficial effects beyond the lowering of blood pres-
sure to reduce stroke incidence. In clinical trials, statins consistently reduced the risk of ischemic stroke in patients with or 
without CHD whereas the data on the effects of other lipid modifying drugs on stroke risk are limited. Approximately 
25% of strokes are recurrent. Antiplatelet therapy is indicated for the prevention of recurrent stroke in patients with a his-
tory of noncardioembolic minor stroke or transient ischemic attack (TIA). Although clinicians may choose acetylsalicylic 
acid (ASA) as first-line therapy for secondary prevention, clinical guidelines and evidence from trials suggest that ASA 
may not be the most effective strategy. A recent review discussed results from clinical trials that have compared the effi-
cacy of ASA monotherapy versus ASA + extended release dipyridamole in secondary stroke prevention. Therefore it is 
difficult to extrapolate the real benefit of pharmacological prevention strategies against atherothrombotic subtype for ex-
cellence in the TOAST classification subtype that is represented by the LAAS and also with regard to lacunar subtype as 
an expression of lipohyalinosis process which is a further aspect of atherosclerosis. 
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INTRODUCTION  
 Categorization of subtypes of ischemic stroke has had 
considerable study, but definitions are hard to formulate and 
their application for diagnosis in an individual patient is of-
ten problematic. 
 In the past, classifications have been based primarily on 
risk factor profiles, clinical features of the stroke, and the 
findings on brain imaging studies (computed tomography 
[CT] or magnetic resonance imaging [MRI]). Yet, clinical 
and brain imaging features overlap and are not specific for 
any particular subtype of ischemic stroke. 
 Determining the cause of stroke does influence choices 
for management. 
 In 1993 Adams et al [1] for the Trial of Org 10172 in 
Acute Stroke Treatment (TOAST), a placebo-controlled, 
randomized, blinded study of the low-molecular-weight 
heparinoid given to patients within 24 hours after stroke, 
developed a system for diagnosis of subtype of ischemic 
stroke that uses components of existing diagnostic schemes. 
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 The TOAST classification system includes five categories:  
 1) Large-artery atherosclerosis, 2) Cardioembolism, 3) 
Small-artery occlusion (lacune), 4) Stroke of other deter-
mined etiology, and 5) Stroke of undetermined etiology. 
 Diagnoses are based on clinical features and on data col-
lected by tests such as brain imaging (CT/MRI), cardiac im-
aging (echocardiography, etc.), duplex imaging of extracra-
nial arteries, arteriography, and laboratory assessments for a 
prothrombotic state. 
 Large-artery atherosclerosis. These patients have clini-
cal and brain imaging findings of either significant (>50%) 
stenosis or occlusion of a major brain artery or branch corti-
cal artery, presumably due to atherosclerosis.  
 Clinical findings include those of cerebral cortical im-
pairment (aphasia, neglect, restricted motor involvement, 
etc.) or brain stem or cerebellar dysfunction. A history of 
intermittent claudication, transient ischemic attacks (TIAs) in 
the same vascular territory, a carotid bruit, or diminished 
pulses helps support the clinical diagnosis. Cortical or cere-
bellar lesions and brain stem or subcortical hemispheric in-
farcts greater than 1.5 cm in diameter on CT or MRI are con-
sidered to be of potential large-artery atherosclerotic origin. 
Supportive evidence by duplex imaging or arteriography of a 
stenosis of greater than 50% of an appropriate intracranial or 
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extracranial artery is needed. Diagnostic studies should ex-
clude potential sources of cardiogenic embolism. The diag-
nosis of stroke secondary to largeartery atherosclerosis can-
not be made if duplex or arteriographic studies are normal or 
show only minimal changes. 
 Cardioembolism: This category includes patients with 
arterial occlusions presumably due to an embolus arising in 
the heart. Cardiac sources are divided into high-risk and me-
dium-risk groups based on the evidence of their relative pro-
pensities for embolism. At least one cardiac source for an 
embolus must be identified for a possible or probable diag-
nosis of cardioembolic stroke. Clinical and brain imaging 
findings are similar to those described for large-artery athe-
rosclerosis. 
 Small-artery occlusion (lacune): This category includes 
patients whose strokes are often labeled as lacunar infarcts in 
other classifications. The patient should have one of the tra-
ditional clinical lacunar syndromes and should not have evi-
dence of cerebral cortical dysfunction. 
 The patient should also have a normal CT/MRI examina-
tion or a relevant brain stem or subcortical hemispheric le-
sion with a diameter of less than 1.5 cm demonstrated  
 Acute stroke of other determined etiology: This cate-
gory includes patients with rare causes of stroke, such as 
nonatherosclerotic vasculopathies, hypercoagulable states, or 
hematologic disorders.  
 Diagnostic studies such as blood tests or arteriography 
should reveal one of these unusual causes of stroke.  
 Stroke of undetermined etiology: In several instances, 
the cause of a stroke cannot be determined with any degree 
of confidence. Some patients will have no likely etiology 
determined despite an extensive evaluation. In others, no 
cause is found but the evaluation is cursory. 
 This category also includes patients with two or more 
potential causes of stroke so that the physician is unable to 
make a final diagnosis. 
 Atherosclerosis is a complex disease, and our current 
understanding represents a synthesis of numerous hypotheses 
developed over the past century and a half [2]. Currently, the 
pathogenesis of atherosclerosis is thought to involve a se-
quence of biologic events within the intima of the vessel wall 
which includes vascular injury, monocyte recruitment and 
macrophage formation, lipid deposition, platelet degranula-
tion and thrombosis, and vascular smooth muscle cell migra-
tion, proliferation and extracellular matrix synthesis [3]. 
 On this basis drugs to prevent atherosclerosis complica-
tion such as thrombotic strokes, should be drugs able to pre-
vent the accumulation of intravascular fat, reduce vascular 
proliferation, decease blood pressure levels with the resulting 
shear stress, reduce platelet aggregation, and possibly par-
tially or totally reverse carotid plaques.  
 Lacunes are small areas inside the brain where poor 
blood flow has starved a group of cells of oxygen. Lack of 
oxygen causes the cells to die. When this happens, it is called 
a stroke or an infarction. A lacunar infarct is a tiny stroke 
that often causes no neurologic symptoms (these are also 
referred to as “silent” strokes). While many healthy people 
have silent lacunes, some association has been shown 
between having lacunes and having mild problems with 
thinking. When a person has a lot of lacunes, or when they 
occur in certain key parts of the brain, dementia may 
develop. When the dementia is due to many small strokes, it 
is called vascular dementia (“vascular” means “related to 
blood vessels,” and blockage of the blood vessel causes 
strokes. Lacunar stroke is a cerebral infarct that occurs in the 
territory of a single perforator artery. The mechanism that 
underlies lacunar infarct is presumed to be the small vessel 
disease [The nature of this microangiopathy includes lipo-
hyalinosis secondary to the effects of hypertension, microat-
heroma of the perforator artery and, less common, emboli 
from heart or large vessels.  
 Long term data suggest that up to 25% of patients with 
lacunar infarcts have a second stroke within 5 years (2). A 
Embolism of cardiac origin accounts for about one fifth of 
ischaemic strokes. Strokes due to cardioembolism are in 
general severe and prone to early recurrence. Non-valvular 
atrial fibrillation is the commonest cause of cardioembolic 
stroke. Despite its enormous preventive potential, continuous 
oral anticoagulation is prescribed for less than half of pa-
tients with atrial fibrillation who have risk factors for cardi-
oembolism and no contraindications for anticoagulation. 
Alternatives to oral anticoagulation in this setting include 
safer and easier to use antithrombotic drugs and definitive 
treatment of atrial fibrillation. Available evidence does not 
support routine immediate anticoagulation of acute cardi-
oembolic stroke. 
 Nevertheless, most trials did not evaluated stroke accord-
ing stroke subtypes and on this basis few studies exist about 
the role of drug prevention in lacunar stroke or cardioem-
bolic stroke, and only more recent studies considered stroke 
prevention in relation of clinical subtypes of stroke classified 
according TOAST subtype  
ATHEROTHROMBOTIC STROKE PREVENTION 
Blood Pressure Reduction 
 Blood pressure (BP) is the most important determinant of 
the risk of stroke. A small reduction in BP results in a sub-
stantial reduction of both ischemic and hemorrhagic stroke. 
Any of the commonly used antihypertensive drugs lower the 
incidence of stroke, with larger reductions in BP resulting in 
larger reductions in risk [12]. Experimental evidence has 
linked the renin-angiotensin system (RAS) to the development 
and progression of cerebrovascular disease. Inhibition of the 
RAS has beneficial cerebrovascular effects and may reduce 
the risk of stroke in a manner possibly independent from the 
alterations of BP. Treatment of hypertension significantly 
reduces the risk of stroke; however, it is unclear whether all 
antihypertensive agents are equivalent in this regard. Angio-
tensin-converting enzyme (ACE) inhibitors have been shown 
to reduce the risk of cardiovascular events, including stroke. 
Although attenuation of the renin-angiotensin system (RAS) 
is often credited with the blood pressure-independent effects 
of this class of agents, this hypothesis has not been con-
firmed with regard to the end point of stroke. The Captopril 
Prevention Project (CAPPP) [4] found fatal or nonfatal 
stroke to be 1.25 times more frequent in patients randomized 
to captopril than in those assigned to conventional therapy 
with diuretics, b blockers, or both.  
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 Diabetes mellitus is a strong risk factor for cardiovascu-
lar and renal disease. HOPE study [5] investigated whether 
the angiotensin-converting-enzyme (ACE) inhibitor ramipril 
can lower these risks in patients with diabetes. In this trial 
3577 people with diabetes included in the Heart Outcomes 
Prevention Evaluation study, aged 55 years or older, who 
had a previous cardiovascular event or at least one other car-
diovascular risk factor, no clinical proteinuria, heart failure, 
or low ejection fraction, and who were not taking ACE in-
hibitors, were randomly assigned ramipril (10 mg/day) or 
placebo, and vitamin E or placebo, according to a two-by-
two factorial design. Ramipril lowered the risk of the com-
bined primary outcome by 25% (95% CI 12-36, p=0.0004), 
myocardial infarction by 22% (6-36), stroke by 33% (10-50), 
cardiovascular death by 37% (21-51), total mortality by 24% 
(8-37), revascularisation by 17% (2-30), and overt nephropa-
thy by 24% (3-40, p=0.027). After adjustment for the 
changes in systolic (2.4 mm Hg) and diastolic (1.0 mm Hg) 
blood pressures, ramipril still lowered the risk of the com-
bined primary outcome by 25% (12-36, p=0.0004). This trial 
showed that ramipril was beneficial for cardiovascular events 
and overt nephropathy in people with diabetes. The cardio-
vascular benefit was greater than that attributable to the de-
crease in blood pressure. This treatment represents a vascu-
loprotective and renoprotective effect for people with diabe-
tes. 
 An ACE inhibitor was effective compared with placebo 
in the PROGRESS trial [6]
. 
The perindopril protection 
against recurrent stroke study (PROGRESS) was designed to 
determine the effects of a blood-pressure-lowering regimen 
in hypertensive and non-hypertensive patients with a history 
of stroke or transient ischaemic attack. 6105 individuals from 
172 centres in Asia, Australasia, and Europe were randomly 
assigned active treatment (n=3051) or placebo (n=3054). 
Over 4 years of follow up, active treatment reduced blood 
pressure by 9/4 mm Hg. 307 (10%) individuals assigned ac-
tive treatment suffered a stroke, compared with 420 (14%) 
assigned placebo (relative risk reduction 28% [95% CI 17-
38], p<0.0001). Active treatment also reduced the risk of 
total major vascular events (26% [16-34]). There were simi-
lar reductions in the risk of stroke in hypertensive and non-
hypertensive subgroups (all p<0.01). Combination therapy 
with perindopril plus indapamide reduced blood pressure by 
12/5 mm Hg and stroke risk by 43% (30-54). Single-drug 
therapy reduced blood pressure by 5/3 mm Hg and produced 
no discernable reduction in the risk of stroke. 
 More recently in a substudy of PROGRESS trial [7] dur-
ing a mean of 3.9 years of follow-up, active treatment re-
duced the absolute rates of ischemic stroke from 10% to 8% 
(relative risk reduction [RRR], 24%; 95% confidence inter-
val [CI], 10 to 35) and the absolute rates of intracerebral 
hemorrhage from 2% to 1% (RRR, 50%; 95% CI, 26 to 67). 
The relative risk of any stroke during follow-up was reduced 
by 26% (95% CI, 12 to 38) among patients whose baseline 
cerebrovascular event was an ischemic stroke and by 49% 
(95% CI, 18 to 68) among those whose baseline event was 
an intracerebral hemorrhage. There was no evidence that 
treatment effects were modified by other drug therapies (an-
tiplatelet or other antihypertensive agents), residual neuro-
logical signs, atrial fibrillation, or the time since the last 
cerebrovascular event. In this trial beneficial effects of a per-
indopril-based treatment regimen were observed for all 
stroke types and all major clinical subgroups studied. These 
data suggest that effective blood pressure-lowering therapy 
should be routinely considered for all patients with a history 
of cerebrovascular events. 
 Thus, it would appear that ACE inhibitor therapy and -- 
in ACE inhibitor-intolerant patients, angiotensin receptor 
blocker treatment -- is warranted if primary prevention is 
contemplated in a high-risk patient or secondary prevention 
is being considered in a patient already having sustained a 
cerebrovascular event. 
 Some studies in primary prevention of stroke, acute 
stroke, and secondary prevention show advantages for ARBs 
beyond controlling BP alone. In primary prevention, the 
LIFE randomized trial showed a significant difference in 
stroke rate in favor of losartan compared with atenolol de-
spite similar reductions in BP. In acute stroke, the role of 
hypertension and its treatment remains controversial. AC-
CESS, however, suggested that an ARB is safe in hyperten-
sive acute stroke patients and may offer advantages inde-
pendent from BP control 
 Angiotensin II receptor blockers (ARBs) selectively 
block the angiotensin II subtype I receptor, which results in a 
reflexive increase in levels of angiotensin II and unopposed 
activation of angiotensin II subtype 2 receptors. Some clini-
cal trials even suggest that ACE inhibitors and angiotensin II 
type 1 receptor antagonists (angiotensin receptor blockers 
[ARBs] exert cerebroprotective effects beyond BP lowering, 
but the evidence is controversial. Studies on specific protec-
tive actions of antihypertensive drugs are generally ham-
pered by the fact that any treatment-related difference in BP 
may play a dominant role in the prevention of stroke. There 
are also indications that the protective potency of ARBs 
might be superior to that of ACE inhibitors, due to their dif-
ferential activation of angiotensin II type 2 receptors, but the 
clinical relevance of this mechanism is unclear. In secondary 
stroke prevention, there are very few antihypertensive trials. 
These trials show that BP lowering is at least as successful as 
in primary prevention, but the absolute stroke risk is much 
higher. 
 Left ventricular hypertrophy (LVH) is a strong independ-
ent indicator of risk of cardiovascular morbidity and death. 
LIFE study [8] is a randomised, parallel-group trial in 9193 
participants aged 55-80 years with essential hypertension 
(sitting blood pressure 160-200/95-115 mm Hg) and LVH 
ascertained by electrocardiography (ECG). Authors assigned 
participants once daily losartan-based or atenolol-based anti-
hypertensive treatment for at least 4 years and until 1040 
patients had a primary cardiovascular event (death, myocar-
dial infarction, or stroke). Blood pressure fell by 30.2/16.6 
(SD 18.5/10.1) and 29.1/16.8 mm Hg (19.2/10.1) in the 
losartan and atenolol groups, respectively. The primary com-
posite endpoint occurred in 508 losartan (23.8 per 1000 pa-
tient-years) and 588 atenolol patients (27.9 per 1000 patient-
years; relative risk 0.87, 95% CI 0.77-0.98, p=0.021). 204 
losartan and 234 atenolol patients died from cardiovascular 
disease (0.89, 0.73-1.07, p=0.206); 232 and 309, respec-
tively, had fatal or non-fatal stroke (0.75, 0.63-0.89, 
p=0.001); and myocardial infarction (non-fatal and fatal) 
occurred in 198 and 188, respectively (1.07, 0.88-1.31, 
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p=0.491). Losartan seems to confer benefits beyond reduc-
tion in blood pressure 
 As part of the LIFE study, in a double-masked, random-
ised, parallel-group trial [9] researchers assigned a group of 
1195 patients with diabetes, hypertension, and signs of left-
ventricular hypertrophy (LVH) on electrocardiograms losar-
tan-based or atenolol-based treatment. Mean age of patients 
was 67 years (SD 7) and mean blood pressure 177/96 mm 
Hg (14/10) after placebo run-in. We followed up patients for 
at least 4 years (mean 4.7 years [1.1]). We used Cox regres-
sion analysis with baseline Framingham risk score and elec-
trocardiogram-LVH as covariates to compare the effects of 
the drugs on the primary composite endpoint of cardiovascu-
lar morbidity and mortality (cardiovascular death, stroke, or 
myocardial infarction).: Mean blood pressure fell to 146/79 
mm Hg (17/11) in losartan patients and 148/79 mm Hg 
(19/11) in atenolol patients. The primary endpoint occurred 
in 103 patients assigned losartan (n=586) and 139 assigned 
atenolol (n=609); relative risk 0.76 (95% CI 0.58-.98), 
p=0.031. 38 and 61 patients in the losartan and atenolol 
groups, respectively, died from cardiovascular disease; 0.63 
(0.42-0.95), p=0.028. Mortality from all causes was 63 and 
104 in losartan and atenolol groups, respectively; 0.61 (0.45-
0.84), p=0.002. On this basis Losartan was more effective 
than atenolol in reducing cardiovascular morbidity and mor-
tality as well as mortality from all causes in patients with 
hypertension, diabetes, and LVH. Losartan seems to have 
benefits beyond blood pressure reduction 
 More recently, in MOSES study [10] total of 1405 well-
defined, high-risk hypertensives with cerebral event during 
the last 24 months (proven by cerebral computed tomogra-
phy scan or nuclear magnetic resonance) were randomized to 
eprosartan or nitrendipine (mean follow-up 2.5 years). Pri-
mary end point was the composite of total mortality and all 
cardiovascular and cerebrovascular events, including all re-
current events. Blood pressure was reduced to a comparable 
extent without any significant differences between the 2 
groups during the whole study period (150.7/84 mm Hg and 
152.0/87.2 mm Hg with eprosartan and nitrendipine therapy 
to 137.5/80.8 mm Hg and 136.0/80.2 mm Hg, respectively, 
confirmed by ambulatory blood pressure monitoring). 
Moreover, already after 3 months, normotensive mean values 
were achieved, and 75.5% reached values <140/90 mm Hg 
with the eprosartan regimen and 77.7% with the nitrendipine 
regimen. During follow-up, in total, 461 primary events oc-
curred: 206 eprosartan and 255 nitrendipine (incidence den-
sity ratio [IDR], 0.79; 95% CI, 0.66 to 0.96; P=0.014). Car-
diovascular events were: 77 eprosartan and 101 nitrendipine 
(IDR, 0.75; 95% CI, 0.55 to 1.02; P=0.06); cerebrovascular 
events: 102 eprosartan and134 nitrendipine (IDR, 0.75; 95% 
CI, 0.58 to 0.97; P=0.03). The Morbidity and Mortality After 
Stroke, Eprosartan Compared With Nitrendipine for Secon-
dary Prevention (MOSES) study was the first to compare an 
angiotensin II type 1 receptor antagonist with a calcium an-
tagonist in secondary stroke prevention. In these high-risk 
hypertensive stroke patients, an early normotensive and 
comparable blood pressure was achieved. The combined 
primary end point was significantly lower in the eprosartan 
group. The MOSES study showed that eprosartan prevented 
vascular events more effectively than nitrendipine, despite 
similar BP-lowering effects [11,13,15]. 
Statins in Thrombotic Stroke Prevention 
 Whereas dyslipidemia is a major risk factor for coronary 
heart disease (CHD), its role in the pathogenesis of ischemic 
stroke is less clear. Epidemiological studies have provided 
conflicting findings regarding the association of dyslipide-
mia with ischemic stroke. Overall, elevated LDL-C levels 
appear to increase the risk of ischemic stroke. Low HDL-C 
levels also appear to be associated with a greater risk 
whereas the importance of high triglyceride levels is less 
clear. The discordant results of observational studies might 
result from the heterogeneity of stroke, since dyslipidemia is 
less likely to play a major role in the pathogenesis of some 
ischemic stroke subtypes (e.g. lacunar and cardioembolic 
strokes) and elevated LDL-C levels might increase the risk 
of hemorrhagic stroke. In clinical trials, statins consistently 
reduced the risk of ischemic stroke in patients with or with-
out CHD whereas the data on the effects of other lipid 
modifying drugs on stroke risk are limited [16]. 
 Over the past decade, statins have been proved to signifi-
cantly decrease coronary events in the primary and secon-
dary prevention of coronary artery disease. Recent clinical 
trials have indicated that statins significantly reduce stroke 
risk in patients with vascular disease.  
 Throughout the usual LDL cholesterol range in Western 
populations, lower blood concentrations are associated with 
lower cardiovascular disease risk. In such populations, there-
fore, reducing LDL cholesterol may reduce the development 
of vascular disease, largely irrespective of initial cholesterol 
concentrations. In MRC/BHF Heart Protection Study [17] 
536 UK adults (aged 40-80 years) with coronary disease, 
other occlusive arterial disease, or diabetes were randomly 
allocated to receive 40 mg simvastatin daily (average com-
pliance: 85%) or matching placebo (average non-study statin 
use: 17%). All-cause mortality was significantly reduced 
(1328 [12.9%] deaths among 10,269 allocated simvastatin 
versus 1507 [14.7%] among 10,267 allocated placebo; 
p=0.0003), due to a highly significant 18% (SE 5) propor-
tional reduction in the coronary death rate (587 [5.7%] vs 
707 [6.9%]; p=0.0005), a marginally significant reduction in 
other vascular deaths (194 [1.9%] vs 230 [2.2%]; p=0.07), 
and a non-significant reduction in non-vascular deaths (547 
[5.3%] vs 570 [5.6%]; p=0.4). There were highly significant 
reductions of about one-quarter in the first event rate for 
non-fatal myocardial infarction or coronary death (898 
[8.7%] vs 1212 [11.8%]; p<0.0001), for non-fatal or fatal 
stroke (444 [4.3%] vs 585 [5.7%]; p<0.0001), and for coro-
nary or non-coronary revascularisation (939 [9.1%] vs 1205 
[11.7%]; p<0.0001). For the first occurrence of any of these 
major vascular events, there was a definite 24% (SE 3; 95% 
CI 19-28) reduction in the event rate (2033 [19.8%] vs 2585 
[25.2%] affected individuals; p<0.0001). During the first 
year the reduction in major vascular events was not signifi-
cant, but subsequently it was highly significant during each 
separate year. More recent studies, such as the Treat to New 
Target (TNT) trial, have confirmed that statins reduced the 
risk of first-ever stroke in patients with coronary artery dis-
ease and in other high-risk populations - mainly diabetics in 
the Heart Protection Study (HPS) and Collaborative Atorvas-
tatin Diabetes Study (CARDS) trial and hypertensives in the 
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) - 
828    Current Vascular Pharmacology, 2013, Vol. 11, No. 6 Tuttolomondo et al. 
even with a normal baseline blood cholesterol level, which 
argues for a global cardiovascular risk-based treatment strat-
egy [18-20].  
 Recently, a meta-analysis [21] reported data from 18 
686 individuals with diabetes (1466 with type 1 and 
17,220 with type 2) in the context of a further 71,370 without 
diabetes in 14 randomised trials of statin therapy. Weighted 
estimates were obtained of effects on clinical outcomes per 
1.0 mmol/L reduction in LDL cholesterol. During a mean 
follow-up of 4.3 years, there were 3247 major vascular 
events in people with diabetes. There was a 9% proportional 
reduction in all-cause mortality per mmol/L reduction in 
LDL cholesterol in participants with diabetes (rate ratio [RR] 
0.91, 99% CI 0.82-1.01; p=0.02), which was similar to the 
13% reduction in those without diabetes (0.87, 0.82-0.92; 
p<0.0001). This finding reflected a significant reduction in 
vascular mortality (0.87, 0.76-1.00; p=0.008) and no effect 
on non-vascular mortality (0.97, 0.82-1.16; p=0.7) in partici-
pants with diabetes. There was a significant 21% propor-
tional reduction in major vascular events per mmol/L reduc-
tion in LDL cholesterol in people with diabetes (0.79, 0.72-
0.86; p<0.0001), which was similar to the effect observed in 
those without diabetes (0.79, 0.76-0.82; p<0.0001). In dia-
betic participants there were reductions in myocardial infarc-
tion or coronary death (0.78, 0.69-0.87; p<0.0001), coronary 
revascularisation (0.75, 0.64-0.88; p<0.0001), and stroke 
(0.79, 0.67-0.93; p=0.0002). Among people with diabetes the 
proportional effects of statin therapy were similar irrespec-
tive of whether there was a prior history of vascular disease 
and irrespective of other baseline characteristics. After 5 
years, 42 (95% CI 30-55) fewer people with diabetes had 
major vascular events per 1000 allocated statin therapy. On 
this basis statin therapy should be considered for all diabetic 
individuals who are at sufficiently high risk of vascular 
events. 
 Statins reduce the incidence of strokes among patients at 
increased risk for cardiovascular disease; whether they re-
duce the risk of stroke after a recent stroke or transient 
ischemic attack (TIA) remains to be established. In Stroke 
Prevention by Aggressive Reduction in Cholesterol levels 
(SPARCL) study [22]. Authors randomly assigned 4731 
patients who had had a stroke or TIA within one to six 
months before study entry, had low-density lipoprotein 
(LDL) cholesterol levels of 100 to 190 mg per deciliter (2.6 
to 4.9 mmol per liter), and had no known coronary heart dis-
ease to double-blind treatment with 80 mg of atorvastatin per 
day or placebo. The primary end point was a first nonfatal or 
fatal stroke. The mean LDL cholesterol level during the trial 
was 73 mg per deciliter (1.9 mmol per liter) among patients 
receiving atorvastatin and 129 mg per deciliter (3.3 mmol 
per liter) among patients receiving placebo. During a median 
follow-up of 4.9 years, 265 patients (11.2 percent) receiving 
atorvastatin and 311 patients (13.1 percent) receiving pla-
cebo had a fatal or nonfatal stroke (5-year absolute reduction 
in risk, 2.2 percent; adjusted hazard ratio, 0.84; 95 percent 
confidence interval, 0.71 to 0.99; P=0.03; unadjusted 
P=0.05). The atorvastatin group had 218 ischemic strokes 
and 55 hemorrhagic strokes, whereas the placebo group had 
274 ischemic strokes and 33 hemorrhagic strokes. The five-
year absolute reduction in the risk of major cardiovascular 
events was 3.5 percent (hazard ratio, 0.80; 95 percent confi-
dence interval, 0.69 to 0.92; P=0.002). The overall mortality 
rate was similar, with 216 deaths in the atorvastatin group 
and 211 deaths in the placebo group (P=0.98), as were the 
rates of serious adverse events. Elevated liver enzyme values 
were more common in patients taking atorvastatin. So In 
patients with recent stroke or TIA and without known coro-
nary heart disease, 80 mg of atorvastatin per day reduced the 
overall incidence of strokes and of cardiovascular events, 
despite a small increase in the incidence of hemorrhagic 
stroke 
 Furthermore, a substudy of SPARCL study [23] tested 
the hypothesis that the benefit of treatment varies according 
to index event stroke subtype. Authors showed for subjects 
randomized to atorvastatin versus placebo, a primary end 
point occurred in 13.1% versus 18.6% of those classified as 
having large vessel disease (LVD, 15.8% of 4,731 partici-
pants), in 13.1% versus 15.5% of those with small vessel 
disease (SVD, 29.8%), in 11.2% versus 12.7% of those with 
ischemic stroke of unknown cause (21.5%), in 7.6% versus 
8.8% of those with TIA (30.9%), and in 22.2% versus 8.3% 
of those with hemorrhagic stroke (HS, 2%) at baseline. There 
was no difference in the efficacy of treatment for either the 
primary end point (LVD hazard ratio [HR] 0.70, 95% confi-
dence interval [CI] 0.49 to 1.02, TIA HR 0.81, CI 0.57 to 
1.17, SVD HR 0.85, CI 0.64 to 1.12, unknown cause HR 
0.87, CI 0.61 to 1.24, HS HR 3.24, CI 1.01 to 10.4; P for 
heterogeneity=0.421), or MCVEs (P for heterogene-
ity=0.360) based on subtype of the index event. As com-
pared to subjects with LVD strokes, those with SVD had 
similar MCVE rates (19.2% versus 18.5% over the course of 
the trial), and similar overall reductions in stroke and 
MCVEs. This study showed that Atorvastatin 80 mg/d is 
similarly efficacious in preventing strokes and other cardio-
vascular events, irrespective of baseline ischemic stroke sub-
type. 
 A recent review [24] considered the evidence showing 
that statins can prevent first or recurrent stroke or improve its 
outcome in subjects at moderate or high risk for cardiovascu-
lar disease (CVD). Data are reviewed according to trial de-
sign (observational or prospective) and baseline CVD risk. 
Two (ASCOT, CARDS) out of five primary CVD preven-
tion statin trials showed a considerable reduction in stroke 
rates. In two (MIRACL and PROVE IT) out of five acute 
coronary syndrome trials, the prevention of first stroke was 
significant. Most secondary prevention trials (4S, CARE, 
LIPID, HPS, GREACE and TNT) showed a beneficial effect 
of statins in stroke prevention. Finally, SPARCL, the only 
secondary stroke prevention trial in subjects without overt 
coronary heart disease (CHD), showed a significant reduc-
tion in total and ischaemic (fatal and nonfatal) stroke rate, 
although a small but significant increase in nonfatal haemor-
rhagic stroke was noted. There was also a significant reduc-
tion in CHD-related events. The possible mechanisms re-
sponsible for statin-associated stroke prevention are dis-
cussed. The evidence suggests the need to consider early and 
long-term statin treatment (with substantial low-density lipo-
protein cholesterol reduction) in all patients at high risk of 
any type of major vascular event, without discriminating 
CHD from stroke. Thus, statins may be beneficial to both the 
heart and the brain. 
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 No study of primary prevention showed stroke reduction 
in patients treated with statins unless the publication of Jupi-
ter Study [25] increased levels of the inflammatory bio-
marker high-sensitivity C-reactive protein predict cardiovas-
cular events. Since statins lower levels of high-sensitivity C-
reactive protein as well as cholesterol, we hypothesized that 
people with elevated high-sensitivity C-reactive protein lev-
els but without hyperlipidemia might benefit from statin 
treatment. This study randomly assigned 17,802 apparently 
healthy men and women with low-density lipoprotein (LDL) 
cholesterol levels of less than 130 mg per deciliter (3.4 mmol 
per liter) and high-sensitivity C-reactive protein levels of 2.0 
mg per liter or higher to rosuvastatin, 20 mg daily, or pla-
cebo and followed them for the occurrence of the combined 
primary end point of myocardial infarction, stroke, arterial 
revascularization, hospitalization for unstable angina, or 
death from cardiovascular causes. The trial was stopped after 
a median follow-up of 1.9 years (maximum, 5.0). Rosuvas-
tatin reduced LDL cholesterol levels by 50% and high-
sensitivity C-reactive protein levels by 37%. The rates of the 
primary end point were 0.77 and 1.36 per 100 person-years 
of follow-up in the rosuvastatin and placebo groups, respec-
tively (hazard ratio for rosuvastatin, 0.56; 95% confidence 
interval [CI], 0.46 to 0.69; P<0.00001), with corresponding 
rates of 0.17 and 0.37 for myocardial infarction (hazard ratio, 
0.46; 95% CI, 0.30 to 0.70; P=0.0002), 0.18 and 0.34 for 
stroke (hazard ratio, 0.52; 95% CI, 0.34 to 0.79; P=0.002), 
0.41 and 0.77 for revascularization or unstable angina (haz-
ard ratio, 0.53; 95% CI, 0.40 to 0.70; P<0.00001), 0.45 and 
0.85 for the combined end point of myocardial infarction, 
stroke, or death from cardiovascular causes (hazard ratio, 
0.53; 95% CI, 0.40 to 0.69; P<0.00001), and 1.00 and 1.25 
for death from any cause (hazard ratio, 0.80; 95% CI, 0.67 to 
0.97; P=0.02). Consistent effects were observed in all sub-
groups evaluated. The rosuvastatin group did not have a sig-
nificant increase in myopathy or cancer but did have a higher 
incidence of physician-reported diabetes 
ANTIPLATELETS IN THROMBOTIC STROKE PRE-
VENTION 
 The importance of antiplatelet agents for both the preven-
tion and treatment of ischemic disease was a concept that 
developed as the consequence of some research that showed: 
(a) the contribution of platelets to both cardiac [26] and ca-
rotid disease, [27]; (b) development of reproducible assays to 
quantify platelet activation [28]. 
 The recognition that all
 
platelet stimuli share a final 
common pathway that is dependent
 
on the surface glycopro-
tein IIb/IIIa (fibrinogen) receptor has
 
resulted in the devel-
opment of various agents which block this
 
receptor and are 
currently the focus for clinical trials. The major antiplatelet 
therapies used for stroke prevention include aspirin, clopi-
dogrel, and dipyridamole Clopidogrel and dipyridamole have 
been studied alone and in combination with aspirin, with 
variable results.  
-Aspirin 
 The antiplatelet efficacy of aspirin in preventing secon-
dary stroke was established by three studies conducted in the 
late 1980s and early 1990s: the Swedish Aspirin Low-dose 
Trial (SALT) [29]. Trials have demonstrated that aspirin—
even in doses as low as 30 mg/day—reduces secondary 
stroke, MI, or vascular death in patients with the placebo-
controlled SALT study showed that aspirin at 75 mg/day 
reduced the rate of recurrent stroke by 18%,7 whereas the 
Dutch TIA and UK-TIA studies showed that the efficacy of 
aspirin was similar across a dose range from 30 to 1,200 
mg/day;8,9 however, higher doses were associated with in-
creased risk for gastrointestinal and bleeding complications 
[30]. Two subsequent studies, the Stroke Prevention in Re-
versible Ischemia Trial (SPIRIT) [31] and the Warfarin ver-
sus Aspirin in Recurrent Stroke Prevention Study (WARSS) 
[32] showed that aspirin was preferable to warfarin in pre-
venting secondary stroke in patients with initial non-
cardioembolic stroke.  
 In 2002, the Antiplatelet Trialists’ Collaboration (APTC) 
[33] conducted a meta-analysis of 197 randomized controlled 
trials and 90 head-to-head comparator trials of antiplatelet 
agents. Results showed a 23% risk reduction in combined 
vascular events (MI, stroke, and vascular death) with aspirin. 
-Dipyridamole 
 As a single agent, dipyridamole has been evaluated for 
prevention of stroke and other vascular events. The Anti-
platelet Trialists’ Collaboration APTC) demonstrated that 
dipyridamole showed 16% odds reduction for stroke, MI, or 
vascular death versus placebo in a meta-analysis of 15 trials. 
Additionally, aspirin plus extended-release dipyridamole 
demonstrated 30% odds reduction for stroke, MI, or vascular 
death versus placebo in a meta-analysis of 46 trials. 
 The Second European Stroke Prevention Study (ESPS-2) 
[34] is one of two studies that evaluated aspirin plus ex-
tended-release dipyridamole for secondary stroke prevention. 
In ESPS-2, 6,602 patients who had a recent ischemic stroke 
or TIA were enrolled in a multicenter, double-blind, placebo-
controlled trial that randomly assigned them to one of four 
treatment groups: aspirin (25 mg, twice daily), extended-
release dipyridamole (200 mg, twice daily), aspirin plus ex-
tended-release dipyridamole, or placebo. Both agents given 
as monotherapy demonstrated an independent and statisti-
cally significant reduction in recurrent stroke (18% and 16%, 
respectively). However, the combination of aspirin plus ex-
tended-release dipyridamole reduced stroke recurrence by 
23% compared with aspirin alone and by 37% compared 
with placebo. Results from ESPS-2 indicate that aspirin plus 
extended-release dipyridamole has significant benefit over 
aspirin alone for prevention of second stroke. 
 Although 4 earlier studies using an immediate-release 
dipyridamole formulation did not show a benefit of combina-
tion therapy with aspirin plus dipyridamole over aspirin 
alone, ESPS-2 and ESPRIT provided consistent evidence of 
benefit with the combination. The ESPRIT Study Group 
included a meta-analysis of six comparative trials, including 
a total of 3,888 patients taking aspirin plus dipyridamole and 
3,907 taking aspirin alone; this analysis demonstrated an 
overall RRR for combination therapy versus aspirin of 18% 
(95% CI, 0.74–0.91) for the composite outcome of vascular 
death, nonfatal stroke, or nonfatal MI. 
 Patients with transient ischaemic attacks (TIA) and minor 
ischaemic strokes are at risk of serious vascular events (death 
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from all vascular causes, non-fatal stroke, or non-fatal myo-
cardial infarction). Their risk of vascular events lies between 
4 and 11 percent per year. Aspirin only, in a daily dose of 30 
mg or more, offers only modest protection in such patients: it 
reduces the incidence of major vascular events by 13 per-
cent. In a single trial, adding dipyridamole (an alternative 
antiplatelet agent) to aspirin was associated with a 22 percent 
reduction in the risk of major vascular events compared with 
aspirin alone. However, a systematic review of all trials of 
antiplatelet agents by the Antithrombotic Trialists' Collabo-
ration showed that, in high risk patients, there was virtually 
no difference between the aspirin-dipyridamole combination 
and aspirin alone [34].  
-Aspirin+dipyridamole  
 Approximately 25% of strokes are recurrent. Antiplatelet 
therapy is indicated for the prevention of recurrent stroke in 
patients with a history of noncardioembolic minor stroke or 
transient ischemic attack (TIA). Although clinicians may 
choose acetylsalicylic acid (ASA) as first-line therapy for 
secondary prevention, clinical guidelines and evidence from 
trials suggest that ASA may not be the most effective strat-
egy. A recent review discussed [35] results from clinical 
trials that have compared the efficacy of ASA monotherapy 
versus ASA + extended release dipyridamole in secondary 
stroke prevention. Relevant randomized experimental and 
clinical studies in patients with a history of minor stroke or 
TIA of non-cardioembolic etiology were identified using a 
search of the US National Library of Medicine database, 
with no limits on publication dates. The primary search 
terms used were secondary stroke prevention, antiplatelet 
therapy, acetylsalicylic acid, ASA, aspirin, aspirin + ex-
tended-release dipyridamole, and combination therapy. Early 
trials of dipyridamole monotherapy or ASA + dipyridamole 
involved small numbers of patients and found no significant 
treatment differences. Two major trials that compared ASA 
monotherapy, dipyridamole monotherapy, and ASA + 
dipyridamole were identified: the Second European Stroke 
Prevention Study (ESPS-2) and the European/Australasian 
Stroke Prevention in Reversible Ischaemia Trial (ESPRIT). 
Efficacy measurements in ESPS-2 found that stroke relative 
risk reductions were 18% (P = 0.013), 16% (P = 0.039), and 
37% (P < 0.001), respectively, compared with placebo for a 
relative risk reduction of 23.1% (P = 0.006) favoring the 
combination over ASA monotherapy. In ESPRIT, patients 
who received ASA + dipyridamole had a 20% relative risk 
reduction versus ASA monotherapy for the composite end 
point of death from all vascular causes, nonfatal stroke, non-
fatal myocardial infarction, or major bleeding complications. 
In ESPS-2, headache was 5% more common with dual ther-
apy compared with ASA monotherapy. ESPRIT found that 
combination treatment was not associated with a higher 
complication rate than ASA monotherapy, but that the rate of 
withdrawal due to adverse events was higher in the group 
that received the combination. Based on the results from 
these 2 large, randomized trials, ASA + dipyridamole was 
more effective than ASA monotherapy as first-line therapy 
for secondary stroke prevention in these patients with a his-
tory of minor stroke or TIA of noncardioembolic etiology. 
- Clopidogrel 
 Clopidogrel has been evaluated as monotherapy and in 
combination with aspirin with regard to its efficacy in pre-
venting secondary stroke. In the Clopidogrel versus Aspirin 
in Patients at Risk of Ischemic Events (CAPRIE) study [36] 
three groups with a recent history of symptomatic cardiovas-
cular disease (stroke, MI, or peripheral arterial disease were 
randomized to clopidogrel 75 mg/day or aspirin 325 mg/day 
to evaluate the composite outcome of ischemic stroke, MI, or 
vascular death as well as the relative safety of each drug. 
Clopidogrel was slightly more effective than aspirin in re-
ducing cumulative risk of stroke, MI, or vascular death in 
patients with symptomatic atherosclerotic vascular disease 
(8.7% RRR; p = 0.043). However, clopidogrel did not dem-
onstrate superiority versus aspirin in preventing recurrent 
stroke among patients with a history of stroke (8% RRR; p = 
0.28), although the study was powered only to demonstrate 
significant differences in the overall population (n = 
19,185). No major safety differences were observed between 
clopidogrel and aspirin, although the rate of serious hemor-
rhage was slightly higher in the aspirin group (1.55 versus 
1.38%).1 
 In the Match Study [36] on the basis of previous trial 
results (including CAPRIE) in patients with cardiac and 
cerebrovascular disease, investigators sought to determine 
whether the addition of aspirin to clopidogrel would further 
reduce the risk of recurrent ischemic attacks in high-risk 
patients after recent ischemic stroke or TIA. Patients were 
included if they had a stroke or TIA within the previous 3 
months and 1 or more of 5 additional high-risk factors within 
the previous 3 years: previous stroke, previous MI, angina, 
diabetes, or symptomatic PAD. The results of MATCH 
showed no significant difference between clopidogrel alone 
and clopidogrel plus aspirin in reducing risk of vascular 
events after stroke or TIA. Although there was an absolute 
risk reduction of 1% and a relative risk reduction of 6.4% 
favoring clopidogrel plus aspirin, the between-group differ-
ences were not statistically significant.  
 Furthermore in the CHARISMA Study (37) a prospec-
tive, multicenter, randomized, double-blind, placebo-
controlled study, 15,603 patients were randomized to receive 
clopidogrel 75 mg/day plus lowdose aspirin (75–162 
mg/day) or placebo plus low-dose aspirin, with median fol-
low-up of 28 months. All patients were 45 years of age or 
older and had either multiple atherothrombotic risk factors or 
a history of documented coronary disease, cerebrovascular 
disease, or symptomatic PAD. Among all patients enrolled 
in CHARISMA, there was no statistically significant differ-
ence between treatment groups in the rates of occurrence of 
the primary efficacy endpoint (clopidogrel plus aspirin 6.8%, 
aspirin alone 7.3%; RR 0.93, 95% CI 0.83–1.05; p = 0.22). 
Patients with multiple risk factors but no clearly established 
vascular disease (primary prevention cohort) did not benefit 
from the addition of clopidogrel to aspirin; instead, adjunc-
tive clopidogrel was associated with a nonsignificant 20% 
relative increase in the rate of primary events, as well as an 
excess in cardiovascular mortality (3.9 versus 2.2%, p = 
0.01). In patients with established cardiovascular disease (the 
secondary prevention cohort), the addition of clopidogrel re-
sulted in a marginally significant clinical benefit regarding 
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the primary endpoint (6.9 versus 7.9% with placebo; RR 
0.88; 95% CI, 0.77–0.998; p = 0.046). Results of the safety 
analysis showed a nonsignificant increase in the primary 
safety endpoint of severe bleeding with clopidogrel; the rate 
of moderate bleeding (that required transfusion) was 2.1% in 
the clopidogrel group and 1.3% in the placebo group (RR, 
1.62; 95% CI, 1.27–2.08; p<0.001). 
 Previous analyses have shown sex-based differences in 
response to several antiplatelet medications. Little is known 
about the efficacy and safety of clopidogrel in women and 
men. A study [41] (performed a meta-analysis of all blinded 
randomized clinical trials comparing clopidogrel and placebo 
(CURE [Clopidogrel in Unstable Angina to Prevent Recur-
rent Events], CREDO [Clopidogrel for the Reduction of 
Events During Observation], CLARITY-TIMI 28 [Clopi-
dogrel as Adjunctive Reperfusion Therapy-Thrombolysis In 
Myocardial Infarction COMMIT [Clopidogrel and Me-
toprolol in Myocardial Infarction Trial], and CHARISMA 
[Clopidogrel for High Atherothrombotic Risk and Ischemic 
Stabilization, Management, and Avoidance] trials), involving 
a total of 79,613 patients, of whom 30% were women. The 
relative efficacy and safety of clopidogrel at reducing car-
diovascular events (cardiovascular death, myocardial infarc-
tion [MI], or stroke) in women and men was estimated using 
random-effects modeling [38,39]. Overall, clopidogrel was 
associated with a highly significant 14% proportional reduc-
tion in the risk of cardiovascular events (odds ratio [OR]: 0.86; 
95% confidence interval [CI]: 0.80 to 0.93), with no signifi-
cant differences in treatment effect between women and 
men. Among the 23,533 women enrolled, there were fewer 
cardiovascular events in the clopidogrel group compared 
with the placebo group (11.0% vs. 11.8%; OR: 0.93; 95% 
CI: 0.86 to 1.01). In women the risk reduction with clopi-
dogrel seemed to be greatest for MI (OR: 0.81; 95% CI: 0.70 
to 0.93), with the effects on stroke (OR: 0.91; 95% CI: 0.69 
to 1.21) or total death (OR: 0.99; 95% CI: 0.90 to 1.08) not 
statistically significant. Among the 56,091 men enrolled, 
there were fewer cardiovascular events in those receiving 
clopidogrel compared with placebo (7.8% vs. 9.0%; OR: 
0.84; 95% CI: 0.78 to 0.91), and the risk reduction was sig-
nificant for MI (OR: 0.83; 95% CI: 0.76 to 0.92), stroke 
(OR: 0.83; 95% CI: 0.71 to 0.96), and total death (OR: 0.91; 
95% CI: 0.84 to 0.97). Clopidogrel increased the risk of ma-
jor bleeding in both women (OR: 1.43; 95% CI: 1.15 to 1.79) 
and men (OR: 1.22; 95% CI: 1.05 to 1.42).  
 Although the most widely studied and prescribed anti-
platelet agent for the prevention of stroke and other serious 
vascular events among high vascular risk patients is aspirin. 
Aspirin inhibits platelet activation by inhibiting platelet cy-
clooxygenase and thromboxane production, and reduces the 
odds of a serious vascular event by about a quarter. The 
thienopyridines (ticlopidine and clopidogrel) inhibit platelet 
activation by a different mechanism to aspirin (blocking the 
ADP receptor on platelets), and so may be more effective 
than aspirin. A very recent review [40] was to determine the 
effectiveness and safety of thienopyridine derivatives (ti-
clopidine and clopidogrel) versus aspirin for the prevention 
of serious vascular events (stroke, myocardial infarction 
(MI) or vascular death) in patients at high risk of such 
events, and specifically in patients with a previous TIA or 
ischaemic stroke. Authors earched the Cochrane Stroke 
Group trials register (most recent search: March 1999) and 
the Antithrombotic Trialists' database. All unconfounded, 
double blind, randomised trials directly comparing ti-
clopidine or clopidogrel with aspirin in high vascular risk 
patients. Four trials involving a total of 22,656 high vascular 
risk patients were included. The trials were of high quality 
and comparable. Aspirin was compared with ticlopidine in 
three trials (3471 patients) and with clopidogrel in one trial 
(19,185 patients). Allocation to a thienopyridine was associ-
ated with a modest, yet statistically significant, reduction in 
the odds of a serious vascular event (12. 0% vs 13.0%; OR: 
0.91, 95% CI: 0.84 to 0.98; 2p = 0.01), corresponding to the 
avoidance of 11 (95% CI: 2 to 19) serious vascular events 
per 1000 patients treated for about two years. There was also 
a reduction in stroke (5.7% vs 6.4%; OR: 0.88, 95% CI: 0.79 
to 0.98; 7 [95% CI: 1 to 13] strokes avoided per 1000 pa-
tients treated for two years). Compared with aspirin, thieno-
pyridines produced a significant reduction in the odds of 
gastrointestinal haemorrhage and other upper gastrointestinal 
upset, but a significant increase in the odds of skin rash and 
of diarrhoea. However, the increased odds of skin rash and 
diarrhoea were greater for ticlopidine than for clopidogrel. 
Allocation to ticlopidine, but not clopidogrel, was associated 
with a significant increase in the odds of neutropenia (2.3% 
vs 0.8%; OR: 2.7, 95% CI: 1.5 to 4.8). In the subset of pa-
tients with TIA/ischaemic stroke, the results were similar to 
those for all patients combined. However, since these pa-
tients are at particularly high risk of stroke, allocation to a 
thienopyridine was associated with a larger absolute reduc-
tion in stroke (10.4% vs 12.0%; OR: 0.86, 95% CI: 0.75 to 
0.97; 16 [95% CI: 3 to 28] strokes avoided per 1000 patients 
treated for two years). On this basis the available randomised 
evidence shows that the thienopyridine derivatives are mod-
estly but significantly more effective than aspirin in prevent-
ing serious vascular events in patients at high risk (and spe-
cifically in TIA/ischaemic stroke patients), but there is un-
certainty about the size of the additional benefit.  
LACUNAR STROKE PREVENTION 
 Lacunar strokes can be defined as strokes in which a 
small branch of a larger blood vessel causes the stroke. Be-
cause of the way blood vessels divide in the brain, lacunar 
strokes tend to occur in areas located away from the surface 
of the brain, where many of the smaller branches of large 
blood vessels are located. 
 As most brain areas perform a limited set of brain func-
tions, the collection of symptoms of a given lacunar stroke 
usually falls within one of five categories of symptoms 
known to be caused by damage in these areas. 
 Lacunar strokes can be defined as strokes of any cause, in 
which the blood vessel that causes the stroke is a small 
branch of a larger blood vessel. Lacunar strokes are typically 
located in "deep areas" of the brain (i.e., away from the sur-
face of the brain), where many of the smaller branches of 
large blood vessels are located. Lacunar infarcts are small 
(0.2 to 15 mm3) noncortical infarcts caused by occlusion of a 
single penetrating branch of a large cerebral artery. These 
branches arise at acute angles from the large arteries of the 
circle of Willis, stem of the middle cerebral artery (MCA), or 
the basilar artery.  
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 Causes of Lacunar Stroke Diabetes mellitus is well rec-
ognized as a risk factor for development of small vessel dis-
ease throughout the body, including the penetrating arteries. 
 Lacunes are caused by occlusion of a single deep pene-
trating artery. The deep penetrating arteries are small non-
branching end arteries (usually smaller than 500 micrometers 
in diameter), which arise directly from much larger arteries 
(eg, the middle cerebral artery, anterior choroidal artery, an-
terior cerebral artery, posterior cerebral artery, posterior 
communicating artery, cerebellar arteries, basilar artery). 
 The accumulation of blood from a cerebral hemorrhage 
can also press on parts of the brain and cause damage. A 
subarachnoid hemorrhage is caused by the rupture of a blood 
vessel that is usually located between the outside of the brain 
and the inside of the skull. The blood vessel at the point of 
rupture is often previously abnormal, such as from an aneu-
rysm (an abnormal ballooning out of the wall of the vessel). 
 Initially, lipohyalinosis was thought to be the predomi-
nant small vessel pathology of lacunes; however, microat-
heroma now is thought to be the most common mechanism 
of arterial occlusion (or stenosis). Occasionally, atheroma in 
the parent artery blocks the orifice of the penetrating artery 
(luminal atheroma), or atheroma involves the origin of the 
penetrating artery (junctional atheroma 
 Nevertheless, The Prevention Regimen for Effectively 
Avoiding Second Strokes (PRoFESS) trial is the largest sec-
ondary stroke prevention study compared extended-release 
dipyridamole plus aspirin (eDYP-ASA) versus clopidogrel 
and telmisartan versus antihypertensive regimens excluding 
angiotensin receptor blockers (ARBs). No statistical differ-
ences were found in either arm for the primary outcome of 
fatal or nonfatal stroke or prespecified secondary end points. 
eDYP-ASA also was associated with increases in major 
hemorrhagic events but not with statistical increases in com-
bined rates of stroke recurrence or hemorrhage. The resulting 
interpretation that eDYP-ASA is "not noninferior" has raised 
questions about how to interpret noninferiority analyses 
 Most studies addressed to stroke prevention not evaluated 
stroke subtypes and on this basis they give informations 
mainly about atherosclerotic stroke prevention 
 Profess Study [42] compared the efficacy and safety of 
two antiplatelet regimens--aspirin plus extended-release 
dipyridamole (ASA-ERDP) versus clopidogrel.  
 In this double-blind, 2-by-2 factorial trial, we randomly 
assigned patients to receive 25 mg of aspirin plus 200 mg of 
extended-release dipyridamole twice daily or to receive 75 
mg of clopidogrel daily. The primary outcome was first re-
currence of stroke. The secondary outcome was a composite 
of stroke, myocardial infarction, or death from vascular 
causes. In this trial stroke subtype was classified according 
TOAST Classification in five subtypes: LAAS, lacunar, CEI, 
ODE and UDE. 
 A total of 20,332 patients were followed for a mean of 
2.5 years. Recurrent stroke occurred in 916 patients (9.0%) 
receiving ASA-ERDP and in 898 patients (8.8%) receiving 
clopidogrel (hazard ratio, 1.01; 95% confidence interval 
[CI], 0.92 to 1.11). The secondary outcome occurred in 1333 
patients (13.1%) in each group (hazard ratio for ASA-ERDP, 
0.99; 95% CI, 0.92 to 1.07). There were more major hemor-
rhagic events among ASA-ERDP recipients (419 [4.1%]) 
than among clopidogrel recipients (365 [3.6%]) (hazard ra-
tio, 1.15; 95% CI, 1.00 to 1.32), including intracranial hem-
orrhage (hazard ratio, 1.42; 95% CI, 1.11 to 1.83). The net 
risk of recurrent stroke or major hemorrhagic event was 
similar in the two groups (1194 ASA-ERDP recipients 
[11.7%], vs. 1156 clopidogrel recipients [11.4%]; hazard 
ratio, 1.03; 95% CI, 0.95 to 1.11). The trial did not meet the 
predefined criteria for noninferiority but showed similar rates 
of recurrent stroke with ASA-ERDP and with clopidogrel. 
There is no evidence that either of the two treatments was 
superior to the other in the prevention of recurrent stroke.  
 In a substudy of this trial [42] patients who had had an 
ischaemic stroke were randomly assigned in a two by two 
factorial design to receive either 25 mg aspirin (ASA) and 200 
mg extended-release dipyridamole (ER-DP) twice a day or 75 
mg clopidogrel once a day, and either 80 mg telmisartan or 
placebo once per day. The predefined endpoints for this 
substudy were disability after a recurrent stroke, assessed with 
the modified Rankin scale (mRS) and Barthel index at 3 
months, and cognitive function, assessed with the mini-mental 
state examination (MMSE) score at 4 weeks after randomisa-
tion and at the penultimate visit. Analysis was by intention to 
treat. 20,332 patients (mean age 66 years) were randomised 
and followed-up for a median of 2.4 years. Recurrent strokes 
occurred in 916 (9%) patients randomly assigned to ASA with 
ER-DP and 898 (9%) patients randomly assigned to clopi-
dogrel; 880 (9%) patients randomly assigned to telmisartan 
and 934 (9%) patients given placebo had recurrent strokes. 
mRS scores were not statistically different in patients with 
recurrent stroke who were treated with ASA and ER-DP ver-
sus clopidogrel (p=0.38), or with telmisartan versus placebo 
(p=0.61). There was no significant difference in the proportion 
of patients with recurrent stroke with a good outcome, as 
measured with the Barthel index, across all treatment groups. 
Additionally, there was no significant difference in the median 
MMSE scores, the percentage of patients with an MMSE 
score of 24 points or less, the percentage of patients with a 
drop in MMSE score of 3 points or more between 1 month 
and the penultimate visit, and the number of patients with de-
mentia among the treatment groups. There were no significant 
differences in the proportion of patients with cognitive im-
pairment or dementia among the treatment groups. Disability 
due to recurrent stroke and cognitive decline in patients with 
ischaemic stroke were not different between the two antiplate-
let regimens and were not affected by the preventive use of 
telmisartan 
 The PRoFESS trial showed that, among patients with a 
noncardioembolic ischemic stroke, the risks of recurrent 
stroke or the composite of stroke, myocardial infarction, or 
death from vascular causes are similar with aspirin plus ex-
tendedrelease dipyridamole and with clopidogrel. Despite the 
increased risk of hemorrhagic strokes with aspirin plus ex-
tended-release dipyridamole as compared with clopidogrel, 
the net benefit with regard to the risk of recurrent stroke or 
major hemorrhagic event was similar in the two groups. Fur-
thermore, there was no significant difference between the 
two treatments in the risk of fatal or disabling strokes 
 Martin-Sanchez et al [43] conducted an observational 
study using data from the Stroke Unit Data Bank from con-
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secutive patients with cerebral infarction. Variables ana-
lyzed: demographic data, cardiovascular risk factors, treat-
ment with statins at stroke onset, stroke severity, stroke sub-
type, in-hospital complications, length of stay, and functional 
status at discharge (modified Rankin Scale). 
 A total of 2742 patients were included, 1539 were men. 
Mean age was 69.17 years (SD 12.19). Of these, 281 patients 
(10.2%) were receiving statins when admitted. The logistic 
regression analyses showed that previous treatment with 
statins was an independent predictor for better outcome at 
discharge among all strokes (OR, 2.08; 95% CI, 1.39 to 3.1) 
as well as for the atherothrombotic (OR, 2.79; 95% CI, 1.33 
to 5.84) and lacunar strokes (OR, 2.28; 95% CI, 1.15 to 4.52) 
after adjustment for demographic data, risk factors, previous 
treatments, stroke subtypes, stroke severity, in-hospital com-
plications and length of stay. This benefit was not observed 
either in cardioembolic or in other etiology strokes. On this 
basis authors concluded that previous treatment with statins 
is an independent factor associated with good outcomes in 
patients with ischaemic stroke. Atherothrombotic and small 
vessel strokes show the greatest benefit 
 The SPARCL study [23] included patients without dif-
ferentiating stroke subtype, including a high proportion of 
lacunar strokes, whereas the greatest benefit is obtained in 
atherothrombotic strokes. In addition, this study included 
patients with intracerebral hemorrhage, in which the effects 
of statins are controversial. Current recommendations in-
clude the administration of statins in patients with stroke or 
TIA with high cholesterol levels reaching levels of LDL-
cholesterol <100 mg/dL (or <70 mg/dL in those with high 
risk) and in patients with atherothrombotic stroke or TIA 
with normal cholesterol levels 
CARDIOEMBOLIC STROKE PREVENTION 
 Cardioembolic stroke accounts for approximately 15% of 
all strokes and is thought to be one of the more preventable 
types of strokes. Features that have been reported to support 
cardioembolism as a mechanism for ischemic stroke have 
included documented cardiac source of embolism, maximal 
neurologic deficit at onset, multiple cerebrovascular territo-
ries involved, enhanced tendency toward hemorrhagic trans-
formation, enhanced risk of syncope or seizure associated 
with presentation, and lower likelihood of premonitory tran-
sient ischemic attacks. Features that tend to make cardioem-
bolic stroke less likely include significant cerebral athero-
sclerosis, stepwise progression of the neurologic deficit 
within a finite period of time, vascular distribution such as 
entire internal carotid artery territory with combined middle 
cerebral artery and anterior cerebral artery involvement or 
watershed distribution, and premonitory transient ischemic 
attacks. A number of cardiac conditions can promote throm-
boembolism, and there is risk stratification reflective of the 
specific condition or coexistent conditions. Anticoagulant 
therapy generally has been found to be the most effective 
means of preventing cardiogenic brain embolism, but the 
intensity of anticoagulation needs to be optimized to reflect 
the risk-to-benefit ratio for the particular patient. 
 Embolic stroke implies a clot originating from one site 
that then promotes occlusive cerebral artery disease. The 
most common sources of cerebral embolism include the ca-
rotid arteries, specific cardiac disease, and atheromata of the 
aortic arch. It is reported that cardioembolic stroke accounts 
for approximately 15% of all strokes [44]. 
 In Patients with AF, stroke is the most serious and life 
threatening complication [45,46]. There is a fivefold in-
creased risk of stroke and thromboembolism with AF when 
compared to sinus rhythm [46] Furthermore, AF accounts for 
up to one fourth of all cerebrovascular events and AF-related 
strokes are more frequently associated with persistent and 
severe disabilities compared to ischemic events attributable 
to vascular disease [47,48].  
 Treatment with vitamin K-antagonists (VKA) substan-
tially reduces the long-term complications associated with 
cardioembolism [49,50] but despite its proved efficiacy, this 
option continues to be underused, even in eligible and par-
ticulary  
 The risk of stroke varies considerably among the group 
of patients with AF. Prior stroke/TIA, hypertension, advanc-
ing age, and diabetes are consistent independent predictors of 
stroke in patients with atrial fibrillation. 
 There are many ways of classifying stroke risk: In a re-
cent comparison of 12 stroke risk stratification schemes in 
patients with nonvalvular AF, the Stroke Risk in Atrial Fib-
rillation Working Group [51] identified 7 schemes that were 
based directly on eventrate analyses (largely been identified 
from non-OAC arms of clinical trials, and occasionally from 
cohort studies), whereas 5 resulted from expert panel con-
sensus. 
 The most frequently included features were prior 
stroke/TIA (in 100% of schemes), patient age, hypertension 
and diabetes mellitus. Two useful resources stand out in 
clinical practice: the Framingham risk score, derived by 
Wang and colleagues [52], and the CHADS2 score published 
by Gage et al [53]. Both use a five step calculation to predict 
the risk for stroke in patients with AF: the former considers 
age, gender, systolic blood pressure, diabetes, and prior 
stroke or TIA, each category assigned with different grad-
ings, and predicts a 5-year stroke risk in the absence of anti-
coagulation. Concerning the latter, the C stands for recent 
congestive heart failure, the H for hypertension, the A for age 
75 or older, the D for diabetes, and the S for prior stroke or 
TIA. Each category is assigned one point except stroke or 
TIA, which gets two due to its high association with subse-
quent stroke. A high score on this index correlates with a 
raised annual stroke rate.  
 The absence of a regular contraction of the fibrillating 
atria leads to an increase of atrial pressure and dilatation, 
which together with hemoconcentration [54,55], endothelial 
dysfunction, and a prothrombotic state is the prerequisite for 
thrombus formation [56]. Echocardiography and autopsy 
studies have shown that more than 90% of all thrombi in 
patients with AF originating in the left atrium, form in the 
left atrial appendage (LAA) [57-60]. The pathogenesis of 
LAA thrombus formation has not been fully elucidated, but 
the precondition is likely to result from a hypercoagulable 
state explained by Virchow’s triad of thrombogenesis – ie, 
abnormal changes of the vessel wall, blood flow, and blood 
constituents [61,62]. Nowadays, this is translated as follows: 
“Abnormal blood flow” means reduced flow up to stasis due 
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to the lack of contraction in combination with the increase of 
volume and size of the LAA, “abnormal blood constituents” 
are represented by activated coagulation factors and plate-
lets, and “abnormal vessel wall” in this case means structural 
and functional changes of endothelial or endocardial cells 
 Treatment of stroke depends on the etiology of the 
original infarct. Evidence is strong that the optimal 
prevention therapy for cardioembolic stroke is anticoagula- 
tion with warfarin. The European Atrial Fibrillation Trial 
found that warfarin reduces the risk for second strokes in 
patients with atrial fibrillation by two-thirds and is superior 
to antiplatelet agents for preventing cardioembolic strokes 
[62]. Warfarin increases the risk of extracranial bleeding, but 
not severely enough to negate the benefit of reducing stroke 
death and disability. The target international normalized ratio 
(INR) for non-valvular atrial fibrillation is generally two to 
three, although this may be higher for certain prosthetic 
valves. 
 The use of adjusted-dose warfarin for stroke patients with 
atrial fibrillation who do not have significant bleeding risk has 
been advocated in several professional guidelines, [63-65] and 
the benefit has been demonstrated in clinical practice. How-
ever, not all strokes in patients with atrial fibrillation are car-
dioembolic in origin [66,67] and some evidence suggests that 
warfarin may not prevent noncardioembolic strokes [68].  
 In 2001 Evans et al [69] conducted a prospective cohort 
study was to determine whether the subtype of the presenting 
stroke influenced the effectiveness of long-term anticoagula-
tion in preventing recurrence. In relationship of Secondary 
Strokes by Initial Stroke Subtype, Anticoagulation was most 
effective in reducing recurrent stroke in patients assigned a 
cardioembolic stroke initially (10.7% for aspirin versus 3.3% 
for warfarin, P_0.01). This was almost entirely due to a re-
duction in cardioembolic recurrences (8.4% versus 1.9%, 
P_0.01), with no differences in the rate of recurrence result-
ing from other causes. Patients whose initial stroke was clas-
sified as undetermined or lacunar showed no significant dif-
ferences between groups in the rate of stroke recurrence, 
either overall or between subtypes of second stroke. How-
ever, patients presenting with lacunar stroke were more 
likely to have a lacunar recurrence than those in whom the 
first stroke was cardioembolic, regardless of treatment regi-
men. This prospective cohort study confirms the superiority 
of warfarin over aspirin in preventing cardioembolic recur-
rence in stroke patients with atrial fibrillation comparable to 
that seen in randomized controlled trials. However, long-
term anticoagulation did not reduce stroke recurrence in pa-
tients presenting with lacunar strokes despite being in atrial 
fibrillation. prevalence of both atrial fibrillation16 and small-
vessel disease increases with age and because there is a risk 
that some patients may be exposed to the risks of anticoagu-
lation and intracerebral hemorrhage without necessarily 
benefiting from the treatment. Although it is widely recog-
nized that stroke is a heterogeneous condition with diverse 
origin, little attention has been paid to stroke subtyping until 
recently. The importance of stroke subtype and targeting of 
secondary prevention to the individual who has had a rele-
vant stroke rather than any stroke has been recognized in 
patients with carotid stenosis 
 A series of clinical trials have shown the remarkable effi-
cacy of anticoagulation with warfarin compared to placebo 
in reducing stroke risk in patients with AF (Copenhagen 
Atrial Fibrillation Aspirin and Anticoagulation, AFASAK 
[70]; Stroke Prevention in Atrial Fibrillation, SPAF [Stroke 
71]; Boston Area Anticoagulation Trial for Atrial Fibrilla-
tion, BAATAF [72]; Canadian Atrial Fibrillation Anticoagu-
lation, CAFA [73]; and Stroke Prevention in Nonrheumatic 
Atrial Fibrillation, SPINAF [74]. In 2007, Hart and col-
leagues published a meta analysis [75] of the afore men-
tioned 5 primary prevention trials plus one study of secon-
dary prevention [76] and demonstrated a 62% relative risk 
reduction for stroke in patients anticoagulated with vitamin 
K-antagonists (warfarin). 
DISCUSSION 
 Stroke is the most common life-threatening neurological 
disorder. Based on limited acute therapies, clinicians have 
opted to focus on preventive strategies to limit its recurrence. 
Targets for prevention include modifiable risk factors such 
as hypertension, diabetes mellitus, dyslipidemia, cigarette 
smoking, obesity, alcohol use, and physical inactivity among 
others. Most of these prevention strategies may appear to be 
directed mainly towards the prevention of thrombotic stroke, 
 Ischemic stroke prevention has been shown to be effec-
tive in several scenarios: primary prevention, prevention 
after a transient ischemic attack (TIA), and secondary pre-
vention. Dietary, lifestyle, and risk factor modification; use 
of aspirin, ticlopidine, clopidogrel, and warfarin; and carotid 
endarterectomy all have a role in stroke prevention in se-
lected persons. Annual risk assessment, screening, and inter-
vention should be part of a concerted national effort to re-
duce the incidence of the third leading cause of death and the 
number one cause of adult disability in the United States. 
 Medical treatments with clear evidence of benefit in 
terms of stroke prevention include:  
- Lowering blood pressure (BP) after all types of stroke or 
TIA  
- Lowering blood cholesterol with a statin after ischaemic 
stroke or TIA  
- Antiplatelet treatment after ischaemic stroke or TIA  
 Secondary stroke prevention after transient ischemic 
stroke (TIA) or minor stroke is of major importance in order 
to avoid recurrent cerebrovascular events and decrease mor-
bidity and mortality. Systematically review of recently pub-
lished, high-quality studies emphasizing the need for emer-
gency assessment and treatment of patients with TIA and 
minor stroke and to give a comprehensive and distinct over-
view over medical secondary stroke prevention trials per-
formed in these patients. Evaluation and implementation of 
preventive stroke therapy has to be immediate in patients 
with TIA and stroke. For patients with non-cardioembolic 
stroke (thrombotic strokes), antiplatelet agents are the treat-
ment of choice. Aspirin plus extended-release dipyridamole 
and clopidogrel are more effective than aspirin and should be 
used in patients with a high risk of recurrent stroke. Treat-
ment of risk factors such as arterial hypertension and high 
cholesterol is even more important in secondary stroke 
prevention than in primary prevention.  
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 Stroke prevails as a common and devastating disease. 
Epidemiological studies have advanced our understanding of 
stroke risk factors and clinical trials have demonstrated ef-
fective interventions to decrease stroke risk by modifying 
risk factors. Stroke risk factors are classified as traditional 
and novel and may be further divided into modifiable and 
non-modifiable. Ongoing research is exploring further inter-
ventions in the management of traditional risk factors. Future 
research will expand our knowledge about the contribution 
of genetic factors to stroke, their interaction with environ-
mental factors and open exciting avenues for the develop-
ment of new therapies. Twenty percent of the United States 
population will have 80% of all strokes; this estimate is 
based on five established, major risk factors for stroke: hy-
pertension, diabetes mellitus, cigarette smoking, hyperlipi-
demia, and heart disease. Therefore, stroke is not random but 
is generally predictable. It is an ideal target for effective pre-
vention strategies that are simple and inexpensive.  
 Although several intervention trials with ACE-.inhibitors, 
ARBs, other antihypertensives, statins have been shown, 
sometimes in primary prevention and mostly in a secondary 
prevention setting, a significant reduction of stroke inci-
dence, yet few studies, with the exception of some study 
such as PROFESS and a SPARCL subtype, used a TOAST 
subtype oriented analysis. Therefore it is difficult to extrapo-
late the real benefit of pharmacological prevention strategies 
against atherothrombotic subtype for excellence in the 
TOAST classification subtype that is represented by the 
LAAS and also with regard of lacunar subtype as an expres-
sion of lipohyalinosis process which is a further aspect of 
atherosclerosis. More frequently stroke classification in 
clinical trials concerns prognosis with terms such as fatal or 
non fatal that are less likely to reveal thrombotic or embolic 
pathogenesis of brain ischemia.  
 Future studies will be addressed to better tailor preven-
tive strategies on clinical subtypes of stroke so to optimize 
drugs adaptation to real thrombotic ischemic events. Fur-
thermore each ischemic stroke subtype as reported by some 
studies is related to inflammation [77-80] and arterial stiff-
ness [81, 82] in a peculiar way and to date no study had ad-
dressed the effects of secondary prevention with cardiovas-
cular active drugs on these markers in relationship of 
TOAST subtype, so this topic could represent a possible fu-
ture research line.  
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